Cornerstone Wealth Group LLC Purchases 18,889 Shares of Johnson & Johnson $JNJ

Cornerstone Wealth Group LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 75.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 43,879 shares of the company’s stock after acquiring an additional 18,889 shares during the quarter. Cornerstone Wealth Group LLC’s holdings in Johnson & Johnson were worth $8,136,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in JNJ. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson in the second quarter worth approximately $27,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the third quarter worth $28,000. Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the last quarter. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $35,000. Finally, Signature Resources Capital Management LLC grew its holdings in shares of Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 beat, stronger guidance and rising free cash flow: JNJ beat Q4 revenue and EPS expectations, raised FY outlook and guided to materially higher 2026 free cash flow (~$21B), which underpins analyst upgrades and ETF buying interest. ETFs to Buy Post JNJ’s Q4 Earnings Surprise & Bullish Cash Flow View
• Positive Sentiment: Large Scotiabank upgrade: Scotiabank moved to “sector outperform” and raised its target sharply (to $265), signaling confidence in J&J’s growth runway and boosting investor appetite. Johnson & Johnson (JNJ) Gets a Buy from Scotiabank
• Positive Sentiment: Multiple price target raises from analysts: Leerink (+$201→$232) and Sanford C. Bernstein (+$208→$225) (and others including Stifel, BofA) have nudged targets higher, reflecting the quarter and helping push sentiment positive. Leerink Raises Price Target Bernstein Raises Price Target
• Positive Sentiment: Technical/trend signals: MarketBeat highlights a trend‑following buy signal after a post‑earnings pullback — technical confirmation can attract momentum and institutional flows. Trend‑Following Buy Signal
• Positive Sentiment: MedTech strength and product pipeline: MedTech sales growth, product launches and the OTTAVA robotic submission provide a potential high‑growth stream beyond staples like Stelara. MedTech Growth & Product Launches
• Neutral Sentiment: Valuation checks: Coverage pieces are assessing JNJ’s valuation after the rally — some see limited near‑term upside from current levels, which could temper aggressive buying. Valuation After Momentum
• Negative Sentiment: Talc litigation risk: A Special Master allowed plaintiffs’ expert testimony in the talc MDL, keeping litigation risk visible and a potential earnings/cash‑flow overhang. Talc Litigation Update

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Argus set a $210.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 15th. Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Bank of America raised their price objective on Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a report on Thursday. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a report on Wednesday, December 10th. Finally, Citigroup raised their price target on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $224.82.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $220.29 on Friday. The company has a market capitalization of $530.74 billion, a PE ratio of 19.94, a P/E/G ratio of 2.24 and a beta of 0.34. The company has a 50-day simple moving average of $208.35 and a two-hundred day simple moving average of $188.93. Johnson & Johnson has a one year low of $141.50 and a one year high of $222.17. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.46. The business had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period last year, the business earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.